Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: Results of a double-blind, placebo-controlled trial

Journal of Clinical Psychopharmacology

Volumn 28, Issue 2, 2008, Pages 235-239

  Rickels, Karl ^a   Mathew, Sanjay ^b   Banov, Michael D ^c   Zimbroff, Daniel L ^d   Oshana, Scott ^e   Parsons Jr , Edward C ^e   Donahue, Stephen R ^e   Kauffman, Michael ^e   Iyer, Ganesh R ^e   Reinhard Jr , John F ^e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Northwest Behavioral Medicine   (United States)

^d Pacific Clinical Research Medical Group   (United States)

^e Epix Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N [3 [4 [4 (CYCLOHEXYLMETHYLSULFONAMIDO)BUTYL] 1 PIPERAZINYL]PHENYL]ACETAMIDE; PLACEBO;

ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; SCORING SYSTEM; TRANQUILIZING ACTIVITY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANXIETY DISORDERS; CAPSULES; DEPRESSIVE DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEADACHE; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGITIS; NAUSEA; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; RECEPTOR, SEROTONIN, 5-HT1A; SULFONAMIDES; TREATMENT OUTCOME;

EID: 40949124826     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31816774de     Document Type: Article

References (14)

1. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002;63:357-366.
2. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;15(44):77-87.
3. Zhang X, Gainetdinov RR, Beaulieu JM, et al. Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron. 2005;6(45):11-16.
4. 1A receptors induces rapid antidepressant response. Neuropsychopharmacology. 1997;16:333-338.
5. Rickels K, Weisman K, Norstad N, et al. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry. 1982;43:81-86.
6. 1A agonist (PRX-00023) for the treatment of anxiety and depression. J Med Chem. 2006;49:3116-3135.
7. 1A agonist in healthy subjects. J Clin Pharmacol. 2007;47:817-824.
8. Cutler NR, Hesselink JM, Sramek JJ. A phase II multicenter dose-finding, efficacy and safety trial of ipsapirone in outpatients with generalized anxiety disorder. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18:447-463.
9. Rickels K, Schweizer E, DeMartinis N, et al. Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial. J Clin Psychopharmacol. 1997;17:272-277.
10. Khan A, Detke M, Khan SR, et al. Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis. 2003;191:211-218.
11. Judd LL, Rapaport MH, Yonkers KA, et al. Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder. Am J Psychiatry. 2004;161:1864-1871.
12. Perahia DG, Kajdasz DK, Walker DJ, et al. Duloxetine 60 mg once daily in the treatment of milder major depressive disorder. Int J Clin Pract. 2006;60:613-620.
13. Othmer E,Othmer SC. Effect of buspirone on sexual dysfunction in patients with generalized anxiety disorder. J Clin Psychiatry. 1987;48:201-203.
14. Landen M, Eriksson E, Agren H, et al. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol. 1999;19:268-271.